Carmignac Gestion’s Core Laboratories CLB Stock Holding History

Carmignac Gestion’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,044,887	Closed	-$604M	–	27
2014 Q1	$604M	Sell	3,044,887 -92,397	-3%	-$17.4M	4.43%	10
2013 Q4	$599M	Sell	3,137,284 -240,416	-7%	-$44.7M	4.46%	13
2013 Q3	$572M	Sell	3,377,700 -63,989	-2%	-$9.93M	4.32%	10
2013 Q2	$522M	Buy	+3,441,689	New	+$488M	4.35%	10

Other funds holding CLB

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

VAM

Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Carmignac Gestion's CLB Position: Q2 2014 in Review

Carmignac Gestion sold out of Core Laboratories (CLB) in Q2 2014, closing a stake of 3,044,887 shares — an estimated $604M sold.

Carmignac Gestion first reported a position in CLB in Q2 2013 and held it in 4 quarters. The position peaked at $604M in Q1 2014. 346 funds tracked by Wall St. Rank hold CLB as of Q2 2014.

Carmignac Gestion reported no remaining Core Laboratories position as of Q2 2014 after selling out during the quarter.
Carmignac Gestion sold 3,044,887 Core Laboratories shares in Q2 2014, an estimated $604M.
Carmignac Gestion first reported a position in Core Laboratories in Q2 2013 and held it in 4 quarters.
Carmignac Gestion's Core Laboratories position peaked at $604M in Q1 2014.
346 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2014.

Based on Carmignac Gestion's 13F filing for Q2 2014, filed 6 Aug 2014.